NCT06253871 - A Phase 1/1b Study of IAM1363 in HER2 Cancers | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions

HER2 Mutation-Related TumorsHER2HER2-positive Breast CancerHER2 + Breast CancerBrain Metastases from Solid TumorsBrain Metastases from HER2 and Breast CancerCNS MetastasesHER2-Positive Solid TumorsNSCLC (non-small Cell Lung Cancer)HER2-positive Bladder CancerHER2-positive Colorectal CancerHER2 + Gastric CancerHER2-positive Gastroesophageal Cancer

Interventions

DRUG

IAM1363

Oral, immediate release capsules of IAM1363

Trial Locations (12)

22031

RECRUITING

NEXT Oncology - Virginia Cancer Specialists, Fairfax

33709

RECRUITING

Comprehensive Hematology Oncology, St. Petersburg

37203

RECRUITING

SCRI Oncology Partners, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

48109

RECRUITING

University of Michigan, Ann Arbor

49546

RECRUITING

START - Midwest Cancer Research Center, Grand Rapids

73104

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

75039

RECRUITING

NEXT Oncology - Dallas, Dallas

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

78758

RECRUITING

NEXT Oncology - Austin, Austin

84119

RECRUITING

START Mountain Region, West Valley City

90089

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles